Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Casey R. Ager

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0507-700X; OpenAlex author ID A5066060808. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 2

  1. Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration. Co-author DOI 10.1172/jci.insight.169150↗
  2. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. Co-author DOI 10.1136/jitc-2021-003246↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Akash R. Boda · 2 shared papers, 2021–2024 · strength 0.34
  2. Michael A. Curran · 2 shared papers, 2021–2024 · strength 0.34
  3. David R Piwnica-Worms · 1 shared paper, 2024 · strength 0.23
  4. Arthur J. Liu · 1 shared paper, 2024 · strength 0.23
  5. David S. Hong · 1 shared paper, 2024 · strength 0.23
  6. Rishika Prasad · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.